Cost-effectiveness of HPV catch-up vaccination program in women aged 13–24 years in a middle income country
This study evaluated the cost-effectiveness of expanding the current routine human papillomavirus (HPV) vaccination program to women aged 13-24 years in Thailand. A Markov model of HPV infection and cervical cancer was adapted. We compared catch-up cohorts of 13- to 24-year-old women vaccinated with (1) bivalent HPV vaccine (Cervarix Compared to no vaccination, the catch-up vaccination programs decreased the incidence of cervical cancer cases and cancer-related deaths 44.8%-63.4% over a lifetime. Vaccinating with 2vHPV (Cervarix All catch-up vaccination programs for women aged 13 to 24 years produce additional health benefits and reduce healthcare costs. Vaccination with 9vHPV was considered the most cost-effective option.